Sugi Predict

Sugi Predict / Compounds / SCHEMBL9995387

SCHEMBL9995387

SCHEMBL9995387

CN(C)[C@@H](CCO)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 1/20 0.56
▸ CHRNB4 P30926 1/20 0.56
▸ CHRNA3 P32297 1/20 0.56
▸ CHRNA4 P43681 1/20 0.56
▸ TRPA1 O75762 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ HTR2A P28223 3/20 0.45
▸ HRH1 P35367 3/20 0.45
▸ GAA P10253 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ AOC3 Q16853 3/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ SLC6A2 P23975 2/20 0.39
▸ SLC6A4 P31645 2/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5398515 1.00 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL28144244 1.00 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL12071516 1.00 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL28144242 1.00 CHRNB2 (0.56) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
Hydrochloric Acid SCHEMBL17710458 0.98 CHRNB2 (0.54) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
Bromide SCHEMBL28176004 0.98 CHRNB2 (0.54) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL817422 0.83 KDM4E (0.52) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL1205734 0.83 KDM4E (0.52) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL1206432 0.83 KDM4E (0.52) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1
SCHEMBL28295993 0.82 CHRNB2 (0.45) CHRNB2CHRNB4CHRNA3CHRNA4TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955306-B Improved process method of dapoxetine hydrochloride 广州市桐晖药业有限公司 2024-12-10 — — CN claimed
CN-118955306-A Improved process method of dapoxetine hydrochloride 广州市桐晖药业有限公司 2024-11-15 — — CN claimed
CN-113880721-B Synthesis method of dapoxetine 湖南九典制药股份有限公司 2024-05-28 — — CN claimed
CN-113880721-A Synthetic method of dapoxetine 湖南九典制药股份有限公司 2022-01-04 — — CN claimed
CN-106883133-B A kind of preparation method of dapoxetine hydrochloride 南京斯贝源医药科技有限公司 2019-12-03 — — CN claimed
CN-107935868-A A kind of crystal form of 5 hydroxytryptamine reuptake inhibithors and preparation method thereof 广州白云山医药集团股份有限公司白云山制药总厂 2018-04-20 — — CN claimed
CN-106883133-A A kind of preparation method of dapoxetine hydrochloride 南京斯贝源医药科技有限公司 2017-06-23 — — CN claimed
CN-103664660-B A kind of synthetic method of dapoxetine hydrochloride SUZHOU UUGENE BIOPHARMA CO., LTD. (CN) 2015-09-09 — — CN claimed
CN-103664660-A Synthesis method of dapoxetine hydrochloride SUZHOU UUGENE BIOPHARMA CO LTD 2014-03-26 — — CN claimed
WO-2011161690-A1 PROCESSES FOR THE PREPARATION OF (+)-N,N-DIMETHYL-2-[1-(NAPHTHALENYLOXY) ETHYL] BENZENE METHANAMINE AND INTERMEDIATES THEREOF SYMED LABS LIMITED (IN) 2011-12-29 — — WO claimed
CN-1151735-A Benzocycloalkylazolethione derivatives SYNTEX INC (US) 1997-06-11 — — CN claimed
US-20260146064-A1 PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) 2026-05-28 — — US disclosed
WO-2024260347-A1 PH-SENSITIVE MEMBRANE RUPTURE SEQUENCE POLYPEPTIDE AND USE THEREOF 华南理工大学 2024-12-26 — — WO disclosed
CN-118955306-B Improved process method of dapoxetine hydrochloride 广州市桐晖药业有限公司 2024-12-10 — — CN disclosed
CN-118955306-A Improved process method of dapoxetine hydrochloride 广州市桐晖药业有限公司 2024-11-15 — — CN disclosed
CN-102442891-A Preparation method of dapoxetine intermediate compound CHIRAL QUEST BIOCHEMICAL SUZHOU CO LTD 2012-05-09 — — CN disclosed
WO-2011161690-A1 PROCESSES FOR THE PREPARATION OF (+)-N,N-DIMETHYL-2-[1-(NAPHTHALENYLOXY) ETHYL] BENZENE METHANAMINE AND INTERMEDIATES THEREOF SYMED LABS LIMITED (IN) 2011-12-29 — — WO disclosed
WO-2011161690-A1 PROCESSES FOR THE PREPARATION OF (+)-N,N-DIMETHYL-2-[1-(NAPHTHALENYLOXY) ETHYL] BENZENE METHANAMINE AND INTERMEDIATES THEREOF SYMED LABS LIMITED (IN) 2011-12-29 — — WO disclosed
CN-101875666-B Optical pure 1,3-alkamine compound as well as preparation method and application thereof in preparing Dapoxetine and analogues thereof ASTATECH CHENGDU PHARMACEUTICAL CO LTD 2011-12-28 — — CN disclosed
CN-101875666-A Optical pure 1,3-alkamine compound as well as preparation method and application thereof in preparing Dapoxetine and analogues thereof ASTATECH CHENGDU PHARMACEUTICAL CO LTD 2010-11-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146064-A1 PH-SENSITIVE MEMBRANE DISRUPTIVE PEPTIDES AND USE THEREOF LNPK, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, YWHAZ CHRNB2 3001/4885CHRNB4 3118/4885CHRNA3 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.